Q3 Earnings Forecast for APLS Issued By William Blair

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Stock analysts at William Blair issued their Q3 2024 earnings estimates for shares of Apellis Pharmaceuticals in a research note issued to investors on Wednesday, October 16th. William Blair analyst L. Hanbury-Brown expects that the company will post earnings per share of ($0.26) for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.37) per share. William Blair also issued estimates for Apellis Pharmaceuticals’ Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($1.25) EPS and FY2025 earnings at $0.34 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Thursday, August 1st. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The business had revenue of $199.70 million for the quarter, compared to the consensus estimate of $190.89 million. During the same quarter last year, the firm posted ($1.02) EPS. The company’s revenue for the quarter was up 110.2% on a year-over-year basis.

APLS has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Apellis Pharmaceuticals in a research report on Friday, September 20th. UBS Group cut their price objective on shares of Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday, July 31st. Wells Fargo & Company cut their price objective on shares of Apellis Pharmaceuticals from $47.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Tuesday, September 24th. Finally, Mizuho lowered their target price on shares of Apellis Pharmaceuticals from $42.00 to $39.00 and set a “neutral” rating for the company in a research note on Friday, September 20th. Four analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $68.00.

Apellis Pharmaceuticals Stock Up 0.3 %

Shares of Apellis Pharmaceuticals stock opened at $28.00 on Friday. The firm’s 50 day moving average price is $34.16 and its 200-day moving average price is $39.51. The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73. Apellis Pharmaceuticals has a 52-week low of $26.28 and a 52-week high of $73.80. The company has a market cap of $3.40 billion, a P/E ratio of -8.09 and a beta of 0.87.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several large investors have recently made changes to their positions in APLS. Future Financial Wealth Managment LLC acquired a new position in shares of Apellis Pharmaceuticals in the 1st quarter valued at $29,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Apellis Pharmaceuticals in the 1st quarter valued at $89,000. nVerses Capital LLC lifted its stake in shares of Apellis Pharmaceuticals by 300.0% in the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after purchasing an additional 2,100 shares during the period. CWM LLC lifted its stake in shares of Apellis Pharmaceuticals by 299.9% in the 2nd quarter. CWM LLC now owns 4,151 shares of the company’s stock valued at $159,000 after purchasing an additional 3,113 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in shares of Apellis Pharmaceuticals by 1,300.8% in the 1st quarter. Russell Investments Group Ltd. now owns 3,586 shares of the company’s stock valued at $211,000 after purchasing an additional 3,330 shares during the period. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the sale, the director now directly owns 100,000 shares in the company, valued at approximately $3,623,000. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 6.80% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).